Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents

Imeglimin is a promising new oral antihyperglycemic agent that has been studied in clinical trials as a possible monotherapy or add-on therapy to lower fasting plasma glucose and improve hemoglobin A(1c) (1–3, 9). Imeglimin was shown to improve both fasting and postprandial glycemia and to increase...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Physiol Endocrinol Metab
Päätekijät: Perry, Rachel J., Cardone, Rebecca L., Petersen, Max C., Zhang, Dongyan, Fouqueray, Pascale, Hallakou-Bozec, Sophie, Bolze, Sébastien, Shulman, Gerald I., Petersen, Kitt Falk, Kibbey, Richard G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Physiological Society 2016
Aiheet:
Call for Papers
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5005968/
https://ncbi.nlm.nih.gov/pubmed/27406738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajpendo.00009.2016
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia